Feng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feng Li has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Jiang Cao
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China
10 shared publications- Kailin Xu
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
9 shared publications Ling-Yu Zeng
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
9 shared publicationsQing-Yun Wu
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
8 shared publicationsZhen-Yu Li
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
7 shared publicationsMeng-Meng Ma
Blood Diseases Institute
5 shared publications
Latest Publications
- 25 October 2026
- Published by Elsevier in Cellular Signalling
- Vol. 149, 112960
Calsyntenin-2 promotes the pathology of acute myeloid leukemia via activation of the JAK2-STAT3 signaling pathway
- 25 October 2026
- Published by Elsevier in Cellular Signalling
- Vol. 149, 112960
Calsyntenin-2 promotes the pathology of acute myeloid leukemia via activation of the JAK2-STAT3 signaling pathway
- 29 August 2022
- Published by Springer Nature in Cellular Oncology
- Vol. 45 (5) , 1005-1018
Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines
Purpose FLT3 mutations occurred in approximately one third of patients with acute myeloid leukemia (AML). FLT3-ITD mutations caused the constitutive activation of the RAS/MAPK signaling pathway. Ribosomal S6 Kinases (RSKs) were serine/threonine kinases that function downstream of the Ras/Raf/MEK/ERK signaling pathway. However, roles and mechanisms of RSKs inhibitor LJH-685, and combinational effects of LJH-685 and FLT3 inhibitor FF-10101 on AML cells were till unclear. Methods Cell viability assay, CFSE assay, RT-qPCR, Colony formation assay, PI stain, Annexin-V/7-AAD double stain, Western blot, and Xenogeneic transplantation methods were used to used to investigate roles and mechanisms of LJH-685 in the leukemogenesis of AML. Results LJH-685 inhibited the proliferation and clone formation of AML cells, caused cell cycle arrest and induced the apoptosis of AML cells via inhibiting the RSK-YB-1 signaling pathway. MV4-11 and MOLM-13 cells carrying FLT3-ITD mutations were more sensitive to LJH-685 than that of other AML cell lines. Further studies suggested that LJH-685 combined with Daunorubicin or FF- 10101 synergistically inhibited the cell viability, promoted the apoptosis and caused cycle arrest of AML cells carrying FLT3-ITD mutations. Moreover, in vivo experiments also indicated that LJH-685 combined with FF-10101 or Daunorubicin prolonged the survival time of NSG mice and reduced the leukemogenesis of AML. Conclusion Thus, these observations demonstrated combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 showed synergism anti-leukemia effects in AML cell lines with FLT3-ITD mutations via inhibiting MAPK-RSKs-YB-1 pathway and provided new targets for therapeutic intervention especially for AML with FLT3-ITD mutations and Daunorubicin-resistant AML.
- 29 August 2022
- Published by Springer Nature in Cellular Oncology
- Vol. 45 (5) , 1005-1018
Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines
Purpose FLT3 mutations occurred in approximately one third of patients with acute myeloid leukemia (AML). FLT3-ITD mutations caused the constitutive activation of the RAS/MAPK signaling pathway. Ribosomal S6 Kinases (RSKs) were serine/threonine kinases that function downstream of the Ras/Raf/MEK/ERK signaling pathway. However, roles and mechanisms of RSKs inhibitor LJH-685, and combinational effects of LJH-685 and FLT3 inhibitor FF-10101 on AML cells were till unclear. Methods Cell viability assay, CFSE assay, RT-qPCR, Colony formation assay, PI stain, Annexin-V/7-AAD double stain, Western blot, and Xenogeneic transplantation methods were used to used to investigate roles and mechanisms of LJH-685 in the leukemogenesis of AML. Results LJH-685 inhibited the proliferation and clone formation of AML cells, caused cell cycle arrest and induced the apoptosis of AML cells via inhibiting the RSK-YB-1 signaling pathway. MV4-11 and MOLM-13 cells carrying FLT3-ITD mutations were more sensitive to LJH-685 than that of other AML cell lines. Further studies suggested that LJH-685 combined with Daunorubicin or FF- 10101 synergistically inhibited the cell viability, promoted the apoptosis and caused cycle arrest of AML cells carrying FLT3-ITD mutations. Moreover, in vivo experiments also indicated that LJH-685 combined with FF-10101 or Daunorubicin prolonged the survival time of NSG mice and reduced the leukemogenesis of AML. Conclusion Thus, these observations demonstrated combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 showed synergism anti-leukemia effects in AML cell lines with FLT3-ITD mutations via inhibiting MAPK-RSKs-YB-1 pathway and provided new targets for therapeutic intervention especially for AML with FLT3-ITD mutations and Daunorubicin-resistant AML.
- Open Access
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 898474
Effects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines
Polo-like kinase 4 (PLK4), a key regulator of centriole biogenesis, is frequently overexpressed in cancer cells. However, roles and the mechanism of PLK4 in the leukemiagenesis of acute myeloid leukemia (AML) remain unclear. In this study, the PLK4 inhibitor Centrinone and the shRNA knockdown were used to investigate roles and the mechanism of PLK4 in the leukemiagenesis of AML. Our results indicated that Centrinone inhibited the proliferation of AML cells in a dose- and time-dependent manner via reduced the expression of PLK4 both in the protein and mRNA levels. Moreover, colony formation assay revealed that Centrinone reduced the number and the size of the AML colonies. Centrinone induced AML cell apoptosis by increasing the activation of Caspase-3/poly ADP-ribose polymerase (PARP). Notably, Centrinone caused the G2/M phase cell cycle arrest by decreasing the expression of cell cycle-related proteins such as Cyclin A2, Cyclin B1, and Cyclin-dependent kinase 1 (CDK1). Consistent with above results, knockdown the expression of PLK4 also inhibited cell proliferation and colony formation, induced cell apoptosis, and caused G2/M phase cell cycle arrest without affecting cell differentiation. All in all, this study suggested that PLK4 inhibited the progression of AML in vitro, and these results herein may provide clues in roles of PLK4 in the leukemiagenesis of AML.
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 898474
Open AccessEffects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines
Polo-like kinase 4 (PLK4), a key regulator of centriole biogenesis, is frequently overexpressed in cancer cells. However, roles and the mechanism of PLK4 in the leukemiagenesis of acute myeloid leukemia (AML) remain unclear. In this study, the PLK4 inhibitor Centrinone and the shRNA knockdown were used to investigate roles and the mechanism of PLK4 in the leukemiagenesis of AML. Our results indicated that Centrinone inhibited the proliferation of AML cells in a dose- and time-dependent manner via reduced the expression of PLK4 both in the protein and mRNA levels. Moreover, colony formation assay revealed that Centrinone reduced the number and the size of the AML colonies. Centrinone induced AML cell apoptosis by increasing the activation of Caspase-3/poly ADP-ribose polymerase (PARP). Notably, Centrinone caused the G2/M phase cell cycle arrest by decreasing the expression of cell cycle-related proteins such as Cyclin A2, Cyclin B1, and Cyclin-dependent kinase 1 (CDK1). Consistent with above results, knockdown the expression of PLK4 also inhibited cell proliferation and colony formation, induced cell apoptosis, and caused G2/M phase cell cycle arrest without affecting cell differentiation. All in all, this study suggested that PLK4 inhibited the progression of AML in vitro, and these results herein may provide clues in roles of PLK4 in the leukemiagenesis of AML.
- 1 September 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 136, 209-219
Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia
- 1 September 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 136, 209-219
Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia
- 1 July 2019
- Published by Elsevier in Neuroscience Letters
- Vol. 705, 80-86
CEP55 promoted the migration, invasion and neuroshpere formation of the glioma cell line U251
- 1 July 2019
- Published by Elsevier in Neuroscience Letters
- Vol. 705, 80-86
CEP55 promoted the migration, invasion and neuroshpere formation of the glioma cell line U251
- 1 March 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 124, 1123-1131
Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia
- 1 March 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 124, 1123-1131
Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia
- 1 October 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 117, 271-279
Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells
- 1 October 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 117, 271-279
Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells
- 1 September 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 116, 1064-1073
Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms
- 1 September 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 116, 1064-1073
Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms
- Open Access
- 10 July 2018
- Published by Springer Nature in Cell Death & Disease
- Vol. 9 (7) , 1-15
CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia
Downregulation of suppressor of cytokine signalling-1 (SOCS1) is one of the vital reasons for JAK1-STAT3 pathway activation in acute myeloid leukaemia (AML). CUE domain-containing 2 (CUEDC2) was a novel interacting partner of SOCS1 and a positive correlation between the expression of CUEDC2 and SOCS1 was confirmed in primary AML cells and AML cell lines without SOCS1 promoter methylation. We aimed to explore roles of CUEDC2 in regulating ubiquitin-mediated degradation of SOCS1 in the leukaemogenesis of AML.According to in vitro experiments, CUEDC2 overexpression increased the level of SOCS1 protein, suppressed JAK1-STAT3 pathway activation. The suppression of this pathway inhibited AML cells’ proliferation by causing G1 arrest and enhanced AML cells’ sensitivity to cytarabine and idarubicin. Similarity, downregulation of CUEDC2 produced opposite results. Knockout or low expression of CUEDC2 in mouse or AML patients displayed lower overall survival and event-free survival rates, compared with these mouse and AML patients had high-CUEDC2 expression. Mechanistic studies revealed that CUEDC2 overexpression attenuated SOCS1 ubiquitination, facilitated its stabilisation by enhancing SOCS1, Elongin C and Cullin-2 (CUL2) interactions, thus inhibited JAK1-STAT3 pathway and leukaemogenesis of AML. Therefore, our novel findings indicated that CUEDC2 interacted with SOCS1 to suppress SOCS1’s ubiquitin-mediated degradation, JAK1-STAT3 pathway activation and leukaemogenesis of AML.
- 10 July 2018
- Published by Springer Nature in Cell Death & Disease
- Vol. 9 (7) , 1-15
Open AccessCUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia
Downregulation of suppressor of cytokine signalling-1 (SOCS1) is one of the vital reasons for JAK1-STAT3 pathway activation in acute myeloid leukaemia (AML). CUE domain-containing 2 (CUEDC2) was a novel interacting partner of SOCS1 and a positive correlation between the expression of CUEDC2 and SOCS1 was confirmed in primary AML cells and AML cell lines without SOCS1 promoter methylation. We aimed to explore roles of CUEDC2 in regulating ubiquitin-mediated degradation of SOCS1 in the leukaemogenesis of AML.According to in vitro experiments, CUEDC2 overexpression increased the level of SOCS1 protein, suppressed JAK1-STAT3 pathway activation. The suppression of this pathway inhibited AML cells’ proliferation by causing G1 arrest and enhanced AML cells’ sensitivity to cytarabine and idarubicin. Similarity, downregulation of CUEDC2 produced opposite results. Knockout or low expression of CUEDC2 in mouse or AML patients displayed lower overall survival and event-free survival rates, compared with these mouse and AML patients had high-CUEDC2 expression. Mechanistic studies revealed that CUEDC2 overexpression attenuated SOCS1 ubiquitination, facilitated its stabilisation by enhancing SOCS1, Elongin C and Cullin-2 (CUL2) interactions, thus inhibited JAK1-STAT3 pathway and leukaemogenesis of AML. Therefore, our novel findings indicated that CUEDC2 interacted with SOCS1 to suppress SOCS1’s ubiquitin-mediated degradation, JAK1-STAT3 pathway activation and leukaemogenesis of AML.
- 1 May 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 111, 247-254
Mutation of the conserved G66 residue in GS region decreased structural stability and activity of arginine kinase
- 1 May 2018
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 111, 247-254
Mutation of the conserved G66 residue in GS region decreased structural stability and activity of arginine kinase